Notícias

Presidente-executivo da ABIFINA debate a importância estratégica do setor de
fármacos para o Brasil durante o VII Foro Empresarial...

ABIFINA presente em evento de lançamento da consulta pública dos atributos do Novo Processo de Importação do Portal único Siscomex

The repeated emergence of highly pathogenic human coronaviruses as well as their evolving variants highlight the need to develop potent...

It is urgent to develop disease models to dissect mechanisms regulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Here,...

The coronavirus disease emerged in December 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome-related coronavirus 2 (SARS-CoV-2). Its rapid...

Many patients with coronavirus disease 2019 in intensive care units suffer from cytokine storm. Although anti-inflammatory therapies are available to...

The emerging new lineages of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) have marked a new phase of coronavirus disease 2019...

Blood clots are a central feature of coronavirus disease-2019 (COVID-19) and can culminate in pulmonary embolism, stroke, and sudden death....

A Blau Farmacêutica (B3: BLAU3), uma das principais indústrias farmacêuticas da
América Latina focada na produção de medicamentos de...

The emergence of SARS-CoV-2 variants with mutations in major neutralizing antibody-binding sites can affect humoral immunity induced by infection or...

Considering the disruptions imposed by lockdowns and social distancing recommendations, coupled with overwhelmed healthcare systems, researchers worldwide have been exploring...

Direct-acting antivirals for the treatment of COVID-19, which is caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), are needed to complement...